Highest-materiality recent filing
Nuvation Bio Q1 2026 net product revenue $18.5M; net income $5.4M vs loss year ago
Net product revenue $18.5M from IBTROZI; net income $5.4M ($0.02 basic EPS) vs net loss $53.2M year ago.
Nuvation Bio Reports Q4 2025 Revenue of $15.7M, 216 New IBTROZI Patient Starts
IBTROZI (taletrectinib) launched in June 2025; 432 new patient starts by end of Q4 2025, with 216 in Q4 alone.
Nuvation Bio licenses taletrectinib to Eisai for up to €195M; Q4 IBTROZI rev $15.7M
Exclusive license to Eisai for taletrectinib in EU, Canada, Australia, Middle East, India, others; upfront €50M, up to €145M milestones, royalties up to high-teens.
Nuvation Bio discontinues NUV-1511 DDC program; redirects $100-150M to pipeline
Discontinued NUV-1511 due to inconsistent efficacy across cohorts; DDC platform continues.
Nuvation Bio reports Phase 2 ORR 44.4% for safusidenib in IDH1-mutant gliomas
Safusidenib met primary endpoint with 44.4% objective response rate in 27 Japanese patients with grade 2 IDH1-mutant gliomas.
Nuvation Bio Q3 net loss widens to $55.8M; first IBTROZI revenue $7.7M
Net loss $55.8M ($0.16 loss per share) vs. $41.2M ($0.15) in Q3 2024.
Nuvation Bio Q2 net loss $59M; IBTROZI launch with 70 patients in 7 weeks
FDA approved IBTROZI (taletrectinib) for ROS1+ NSCLC on June 11; 70 patients started by July 31.
Nuvation Bio announces FDA approval of IBTROZI (taletrectinib) for ROS1+ NSCLC
FDA approved IBTROZI for adult patients with locally advanced or metastatic ROS1+ NSCLC.
Nuvation Bio Q1 net loss $53.2M; cash $461.7M; taletrectinib PDUFA June 23, 2025
Net loss of $53.2M ($0.16/share) vs $14.8M ($0.07) in Q1 2024; R&D rose to $24.6M, SG&A to $35.4M.
Nuvation Bio: taletrectinib NDA Priority Review, $250M financing, Q4 net loss $49.4M
FDA accepted NDA for taletrectinib with Priority Review; PDUFA goal date June 23, 2025 for advanced ROS1+ NSCLC.
Nuvation Bio secures up to $250M in debt and royalty financing for taletrectinib
$100M loan with Sagard; initial $50M tranche upon FDA approval of taletrectinib by Sep 30, 2025; second $50M upon first US commercial sale by Jun 30, 2026
Nuvation Bio reports Q3 net loss of $41.2M, submits NDA for taletrectinib in ROS1+ NSCLC
Net loss of $41.2M ($0.15 per share) vs $19.6M ($0.09) in Q3 2023; cash of $549.1M at Sept 30.
Nuvation Bio appoints Philippe Sauvage as CFO effective October 7, 2024
Philippe Sauvage appointed CFO; previously SVP Global Head of Operations & Access at Sanofi (2020-2024).
Nuvation Bio shareholders approve 85M share conversion; CEO Hung named Board Chair
Shareholders approved conversion of Series A Preferred into up to 85,120,200 Class A shares; conversion completed Sept 4, resulting in 333.8M Class A shares outstanding.
Nuvation Bio Q2 net loss $462.5M on $425.1M AnHeart charge; halts NUV-868 Phase 2
Net loss of $462.5M ($1.89/share) vs. $20.6M ($0.09) Q2 2023; includes $425.1M acquired IPR&D charge from AnHeart acquisition.
Nuvation Bio files 8-K/A with AnHeart financials and updated taletrectinib clinical data
Acquired AnHeart in Apr 2024; audited AnHeart FY2023 and FY2022 financials included.
Nuvation Bio Q1 net loss $14.8M; completes AnHeart acquisition; cash $597M
Net loss of $14.8M ($0.07 per share) vs $21.7M ($0.10) in Q1 2023.
On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals
Additionally, on February 11, 2025, Dr. Wang notified the board of directors (the “Board”) of his resignation as a member of the Board, effective February 11, 2025.
Effective October 7, 2024 (the “Appointment Date”), the Board of Nuvation Bio Inc. (the “Company”) appointed Philippe Sauvage as the Company’s Chief Financial Officer and Principal Financial Officer.
Max materiality 0.85 · Median 0.75 · Most common event earnings